NCT00563173View on ClinicalTrials.gov

Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Chronic Hepatitis C Virus Infection
Interventions
DRUG

CHRONVAC-C®

DNA vaccine, solution for injection, i.m. administration in combination with electroporation

Trial Locations (2)

SE-141 86

I73 Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm

SE-171 76

Department of Gastroenterology and Hepatology, Karolinska University Hospital, Solna, Stockholm

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

Tripep AB

INDUSTRY

NCT00563173 - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients | Biotech Hunter | Biotech Hunter